The price of Kiora Pharmaceuticals Inc. (NASDAQ:KPRX) shares last traded on Wall Street fell -1.17% to $3.39.
Based on available information, 3 analysts follow Kiora Pharmaceuticals Inc. (NASDAQ:KPRX). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $400.00 and a low of $119.00, we find $259.50. Given the previous closing price of $3.43, this indicates a potential upside of 7465.6 percent. KPRX stock price is now -25.19% away from the 50-day moving average and -70.90% away from the 200-day moving average. The market capitalization of the company currently stands at $3.15M.
Among analysts, 1 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $259.50 as their price target over the next twelve months.
Insiders disposed of 548 shares of company stock worth roughly $1857.72 over the past 1 year. A total of 2.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KPRX stock. A new stake in Kiora Pharmaceuticals Inc. shares was purchased by SPARTAN FUND MANAGEMENT INC. during the first quarter worth $3,000. In total, there are 18 active investors with 7.70% ownership of the company’s stock.
A candlestick chart of Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) showed a price of $3.4700 on Tuesday morning. During the past 12 months, Kiora Pharmaceuticals Inc. has had a low of $2.32 and a high of $71.60. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 2.20. The fifty day moving average price for KPRX is $4.5314 and a two-hundred day moving average price translates $11.6508 for the stock.
The latest earnings results from Kiora Pharmaceuticals Inc. (NASDAQ: KPRX) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$7.2, beating analysts’ expectations of -$8 by 0.8. This compares to -$11.32 EPS in the same period last year. The company reported revenue of $3.7 million for the quarter, compared to $3.04 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.01 percent.
Kiora Pharmaceuticals Inc.(KPRX) Company Profile
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.